FDA approves AZ Imfinzi in new lung cancer use

AstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, and it stopped a trial of its Farxiga after showing “overwhelming efficacy” in chronic ki

New combination trial firms up Venclexta’s prospects in AML

AZ's immunotherapy combo fails in phase 3 lung cancer trial

AstraZeneca’s Imfinzi plus standard chemo improves overall survival in untreated extensive-stage small cell lung cancer – but a combination therapy involving another immunotherapy does not,

Merck, Pfizer’s Bavencio flunks head and neck cancer trial

AZ's cediranib falls short again in ovarian cancer combinati...

AstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it did not improve survival compared with chemotherapy in advanced ovarian cancer, in

Amgen/Allergan's rituximab biosimilar could be $4bn blockbus...

Ten drugs filed with regulators have potential to become billion-sellers by 2025 according to new research, with a near-copy of Roche’s rituximab from Amgen and Allergan showing the mo